You searched for predictions - Page 7 of 12

Weekly reads: stem cell good news, bad news on sickle cell, MS, IPSCs

January 8, 2023 / Professor Paul Knoepfler, Ph.D. / 1 Comment

victoria gray family crispr sickle cell b

Let’s start with some stem cell good news on evolving approaches to treat sickle cell disease involving stem cells. Then on another related front things were more concerning. Stem cell good news on sickle cell disease, a complication Sickle Cell Disease News reports Adding Briquilimab Boosts Success of Sickle Cell Stem Cell Transplant. This is a […]

Weekly reads: stem cell good news, bad news on sickle cell, MS, IPSCs Read More »

Weekly reads: aging, CRISPR delivery, hair, oocytes, paralysis

January 23, 2022 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

The big news of the week was the launch of Altos labs and their ambitious plan to tackle aging through cell therapies. Altos has recruited a large number of top cell biologists away from academia. That team plus top biotech execs and a $3B war chest make Altos one to watch in coming years. I

Weekly reads: aging, CRISPR delivery, hair, oocytes, paralysis Read More »

Weekly science reads: senescence, alt CRISPR, sickle cell update

January 9, 2022 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Is 2022 going to be any better than 2020 or 2021 when it comes to things in general or for biomedical science? Related to the pandemic? It’s too soon to say but if I had to guess right now I’d venture an optimistic view that overall it’s going to be somewhat better by the end

Weekly science reads: senescence, alt CRISPR, sickle cell update Read More »

Weekly stem cell reads: COVID kidney, FDA letter, H3.3, EO Wilson

January 2, 2022 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

Happy New Year and get ready for another 364 more days of stem cell excitement and craziness in 2022. In the next day or two I’ll post my predictions for this new year. Recommended reads EO Wilson obit by Carl Zimmer in NYT. Who’s the next EO Wilson or someone like him with such big impact these

Weekly stem cell reads: COVID kidney, FDA letter, H3.3, EO Wilson Read More »

2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best

December 20, 2021 / Professor Paul Knoepfler, Ph.D. / 3 Comments

A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going

2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »

Our new paper assessing trials of cell therapy for COVID-19

June 14, 2021 / Professor Paul Knoepfler, Ph.D. / 5 Comments

stem cells for covid 19 kim knoepfler 2021

After the COVID-19 pandemic started clinical trials quickly sprouted up to test various kinds of cell therapy for COVID-19 including stem cells. The most common rationale for this approach is to suppress damaging overactive immune responses. Trials of cell therapy for COVID-19 including stem cells I’ve written quite a lot about these cellular medicine and

Our new paper assessing trials of cell therapy for COVID-19 Read More »

Regenerative reads: brain organoids, Clinicaltrials.gov change

February 28, 2021 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Sometimes change takes a very long time, but with brain organoids or advocating for better information for patients at Clinicaltrials.gov, after waiting you can see some interesting developments. These are two of the regenerative medicine stories of the week, along with some striking research papers. Clinicaltrials.gov Some of us have been advocating for improvements at

Regenerative reads: brain organoids, Clinicaltrials.gov change Read More »

Regenerative reads: pig fat, cancer, organoids, more

October 18, 2020 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

Chen-et-al-STM-2020-7a-fat-stem-cells-bone-sm

It’s usually a tossup as to whether my weekly reads skew more towards stem cells/regenerative medicine or cancer. Other times they are more enriched for genomics and epigenetics articles. Seeds of cancer in normal skin, Nature News & Views Engineering synthetic morphogen systems that can program multicellular patterning, Science. Pig fat can be used to

Regenerative reads: pig fat, cancer, organoids, more Read More »

Prop 14 polling on CIRM re-funding stays moderately upbeat

October 5, 2020 / Professor Paul Knoepfler, Ph.D. / 8 Comments

The State of California is considering re-funding its stem cell agency, CIRM, to the tune of more than $5 billion dollars, but the issue has generated surprisingly little media attention. The main coverage has been by David Jensen over at California Stem Cell Report. Prop 14 polling data non-existent in public domain To my knowledge,

Prop 14 polling on CIRM re-funding stays moderately upbeat Read More »

Search Results for: predictions